Seaport Therapeutics, Inc.
SPTXDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Sep 14, 2026
5wMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SPT-300 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Seaport Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Seaport Therapeutics, Inc.'s (SPTX) pipeline across Phase 2. Its lead program is SPT-300 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Seaport Therapeutics, Inc.'s next FDA catalyst?→
Seaport Therapeutics, Inc.'s (SPTX) next tracked catalyst is a Earnings expected September 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SPTX biotech catalysts?→
Add SPTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Seaport Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.